European Psychiatry
2026
Shakila Meshkat, Qiaowei Lin, Rachel Sousa-Ho et al.
Abstract Background Psychedelic-assisted psychotherapy has shown potential for psychiatric disorders. However, the magnitude of symptom change in control groups remains poorly understood. We aim to evaluate within-group effects in control groups and compare them to treatment groups in psychedelic trials. Methods A systematic search was conducted up to 1 July 2025. The study protocol was...
Journal of Substance Use and Addiction Treatment
August 1, 2025
Reinhard Janssen-Aguilar, Shakila Meshkat, Ilya Demchenko et al.
12 citations
Substance Use Disorders (SUDs) involve diminished control, risky use, impaired social interactions, and physical dependence. Despite their global prevalence and burden, treatment options remain limited. Ketamine (KET), an NMDA receptor antagonist, may aid SUD treatment by modulating glutamatergic neurotransmission. This systematic review evaluates KET's role in SUD treatment. This review...
Acta Psychiatrica Scandinavica
August 1, 2022
Helen Liu, Jaimie Kerzner, Ilya Demchenko et al.
To systematically review published research studies and ongoing clinical trials investigating nitrous oxide (N2 O) in psychiatric disorders, providing an up-to-date snapshot of the clinical research landscape. A comprehensive literature search was conducted for studies published until June 2021 using the OVID databases (MEDLINE, Embase, APA PsycInfo) and the clinical trial registries...
Chronic Stress
2022
Sarah Kuburi, Anne-Marie Di Passa, Vanessa K Tassone et al.
14 citations
Preliminary evidence supports the use of psychedelics for major depressive disorder (MDD). However, less attention has been given to the neural mechanisms behind their effects. We conducted a systematic review examining the neuroimaging correlates of antidepressant response following psychedelic interventions for MDD. Through MEDLINE, Embase, and APA PsycINFO, 187 records were identified and 42...